NCT05751187 is a Phase 2 clinical trial of Pembrolizumab in Non-squamous NSCLC, sponsored by Shanghai Chest Hospital.

Who is sponsoring NCT05751187?

NCT05751187 is sponsored by Shanghai Chest Hospital.

What drugs are being tested in NCT05751187?

Interventions in NCT05751187: Pembrolizumab, Bevacizumab, Pemetrexed, Cisplatin, Carboplatin, Folic acid 350-1000 μg, Vitamin B12 1000 μg, Dexamethasone 4 mg.

What condition does NCT05751187 study?

NCT05751187 studies Non-squamous NSCLC.

Is NCT05751187 still recruiting?

NCT05751187 is currently active, enrolled. Last updated 11 March 2026.

Last reviewed 2026-03-11 · How we verify

NCT05751187

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients

Active, enrolled Phase 2 Last updated 11 March 2026

What this trial tests

Phase 2 trial testing Pembrolizumab in Non-squamous NSCLC in 54 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

27 June 2023

Primary endpoint
15 December 2025

30 December 2027

Quick facts

Lead sponsor	Shanghai Chest Hospital
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	54
Start date	27 June 2023
Primary completion	15 December 2025
Estimated completion	30 December 2027
Sites	1 location across China

Drugs / interventions tested

Pembrolizumab (pembrolizumab) — full drug profile →
Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
Pemetrexed — full drug profile →
Cisplatin (cisplatin) — full drug profile →
Carboplatin
Folic acid 350-1000 μg
Vitamin B12 1000 μg
Dexamethasone 4 mg

Conditions studied

Non-squamous NSCLC — all drugs for Non-squamous NSCLC →

Sponsor

Shanghai Chest Hospital

Who can join

Adults 18 to 75, any sex, with Non-squamous NSCLC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to evaluate the efficacy and safety of Pembrolizumab in combination with Bevacizumab and chemotherapy in advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Pembrolizumab

Trials testing the same drug.

NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07275216 — Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Stand · Phase 2 · not yet recruiting
NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT06724042 — Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors · Phase 1 · not yet recruiting
NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting

Other recruiting trials for Non-squamous NSCLC

Currently open trials in the same condition.

NCT04413201 — AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T7 · Phase 4 · active not recruiting

Other Shanghai Chest Hospital trials

Trials by the same sponsor.

NCT07515027 — Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung · NA · recruiting
NCT07479628 — Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma · Phase 2 · not yet recruiting
NCT07528066 — Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC · recruiting
NCT07331727 — Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation · NA · not yet recruiting
NCT07320768 — Renal Denervation Combined With Pulsed Field Ablation to Prevent Blanking-Period Recurrence in Persistent Atrial Fibrill · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05751187 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Chest Hospital
Last refreshed: 11 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05751187.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing